Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
11,072,952
-
Share change
-
+4,151,830
-
Total reported value
-
$32,000,737
-
Put/Call ratio
-
19%
-
Price per share
-
$2.89
-
Number of holders
-
59
-
Value change
-
+$12,950,932
-
Number of buys
-
34
-
Number of sells
-
29
Institutional Holders of CATABASIS PHARMACEUTICALS IN - COM NEW as of Q1 2021
As of 31 Mar 2021,
CATABASIS PHARMACEUTICALS IN - COM NEW was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,072,952 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, SPHERA FUNDS MANAGEMENT LTD., BlackRock Inc., VANGUARD GROUP INC, Ikarian Capital, LLC, Soleus Capital Management, L.P., Alyeska Investment Group, L.P., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, and NORTHERN TRUST CORP.
This page lists
59
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.